Dostarlimab in advanced or recurrent endometrial cancer

被引：0
|
作者：
Lorenz, Judith
机构：
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2023年 / 83卷 / 09期
关键词：
D O I：
10.1055/a-2112-5541
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Primar fortgeschrittene und rezidivierte Endometriumkarzinome haben trotz Carboplatin/Paclitaxel-Chemotherapie eine schlechte Prognose: Das mediane uberleben betragt bei einer solchen Konstellation weniger als 3 Jahre. Profitieren die betroffenen Frauen von einer zusatzlichen Behandlung mit dem Immuncheckpoint-Inhibitor Dostarlimab? Dieser Frage ging eine internationale Phase-III-Studie nach, an der sich 113 Zentren in 19 Landern beteiligten.
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
    Mirza, M. R.
    Chase, D. M.
    Slomovitz, B. M.
    Christensen, R. Depont
    Novak, Z.
    Black, D.
    Gilbert, L.
    Sharma, S.
    Valabrega, G.
    Landrum, L. M.
    Hanker, L. C.
    Stuckey, A.
    Boere, I.
    Gold, M. A.
    Auranen, A.
    Pothuri, B.
    Cibula, D.
    McCourt, C.
    Raspagliesi, F.
    Shahin, M. S.
    Gill, S. E.
    Monk, B. J.
    Buscema, J.
    Herzog, T. J.
    Copeland, L. J.
    Tian, M.
    He, Z.
    Stevens, S.
    Zografos, E.
    Coleman, R. L.
    Powell, M. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (23): : 2145 - 2158
  • [2] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer
    Kasherman, Lawrence
    Ahrari, Soha
    Lheureux, Stephanie
    FUTURE ONCOLOGY, 2021, 17 (08) : 877 - 892
  • [3] Dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer
    Raynaud, Charles
    Rodrigues, Manuel
    BULLETIN DU CANCER, 2024, 111 (05) : 433 - 434
  • [4] Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer
    Shukla, Siddhant
    Patel, Harsh
    Chen, Shuzhen
    Sun, Rainie
    Wei, Liuya
    Chen, Zhe-Sheng
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (03): : 135 - 141
  • [5] A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer"
    Mirza, Mansoor R.
    Chase, Dana M.
    Slomovitz, Brian M.
    Christensen, Rene dePont
    Novak, Zoltan
    Black, Destin
    Gilbert, Lucy
    Sharma, Sudarshan
    Valabrega, Giorgio
    Landrum, Lisa M.
    Hanker, Lars C.
    Stuckey, Ashley
    Boere, Ingrid
    Gold, Michael A.
    Auranen, Annika
    Pothuri, Bhavana
    Cibula, David
    McCourt, Carolyn
    Raspagliesi, Francesco
    Shahin, Mark S.
    Gill, Sarah E.
    Monk, Bradley J.
    Buscema, Joseph
    Herzog, Thomas J.
    Copeland, Larry J.
    Tian, Min
    He, Zangdong
    Stevens, Shadi
    Zografos, Eleftherios
    Coleman, Robert L.
    Powell, Matthew A.
    FUTURE ONCOLOGY, 2025, 21 (02) : 151 - 168
  • [6] Dostarlimab for the treatment of advanced endometrial cancer
    Redondo, Andres
    Gallego, Alejandro
    Mendiola, Marta
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (01) : 1 - 9
  • [7] An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
    Mathews, Cara
    Lorusso, Domenica
    Coleman, Robert L.
    Boklage, Susan
    Garside, Jamie
    ONCOLOGIST, 2022, 27 (12): : 1058 - 1066
  • [8] The comparative clinical effectiveness of dostarlimab versus doxorubicin in the treatment of advanced/recurrent endometrial cancer
    Mathews, Cara
    Lorusso, Domenica
    Coleman, Robert
    Parks, Daniel
    Boklage, Susan
    Garside, Jamie
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S120 - S120
  • [9] Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives
    Bujnak, Alyssa C.
    File, Brittany
    Tewari, Krishnansu S.
    CANCER MANAGEMENT AND RESEARCH, 2025, 17 : 161 - 170
  • [10] Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer
    Huo, Gengwei
    Song, Ying
    Liu, Wei
    Guo, Hua
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345